TECHNOLOGY THAT TRANSFORMS LIVES
Discover our insulin pump therapies and guide your patients to find the right solution to live life on their terms
MiniMed™ 780G system
Automated to help more patients reach glycaemic targets with less effort1,2,3,4 and no fingersticks*.
- Helps patients to reach time in range and HbA1C goals
- Automated to help more patients reach glycaemic targets with less effort1,2,3,4
- Remote follow-ups and automatic uploads of patient data**
* A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
** Refer to MiniMed™ Mobile app User Guide.
SmartGuard™ technology helps prevent highs & Lows
For illustrative puposes only.
* Refers to System User Guide - SmartGuard™ feature. Some interaction required.
MiniMed™ 740G system with Smarguard™ Technology
Predicts and prevents lows before your patients ever feel them.
- Provides advanced protection from hypoglycaemia, compared to CSII Therapy
- 73% less hypoglycaemia
- 79% less time spent in hypoglycaemias
- 84% less severe hypoglycaemmias
*MiniMed™ 740G and the MiniMed™ 640G system share the same therapy algorithm.
MiniMed™ Mio™
Advance
MiniMed™ Quick-set™
Medtronic Extended Infusionsset
MiniMed™ Sure-T™
MiniMed™ Mio™ 30
MiniMed™ Silhouette™
Medtronic Infusion sets and Reservoir for Insulin Pumps
Designed for everybody and every lifestyle.
- Medtronic’s wide range of infusion sets aims to provide patients with the possibility to select the right infusion set for their comfort and safety. This selection should be based on your lifestyle, age, body type, preferences and clinical recommendations.
- Medtronic Reservoirs are also available in 1.8 ml and 3.0 ml sizes in order to meet daily insulin needs.
- Carlson AL, et al. Poster # 97 at the 80th International Conference of the American Diabetes Association, June 2020, Chicago/Virtual.
- Medtronic data on file: Pivotal Trial (Age 14-75). N=157. 16 US sites; 2020.
- Battelino T, et al. Diabetes Care 2019; 42(8): 1593-1603.
- ADA Guidelines of A1C<7.0 – www.Diabetes.org
- Bosi E, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemiaprone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol 2019;7: 462–72.
- Berganstal RM, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N Engl J Med 2010; 363:311-320
